BKYI Nasdaq Services-Prepackaged Software Financials FY2016βFY2025
Bio Key International Inc had $5.9M of revenue in fiscal 2025, down 14.3% on the year before. Over five years, revenue changed +15.9% a year on average.
Last close Β· Oct 23, 2026
$3.39
23.7%Hi! I read Bio Key International Incβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
β14.3%
No. Sales fell 14.3% last year.
Does it make a profit?
β120.6%
No. It lost money last year.
Does profit turn into cash?
β78.8%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 7
Weak. It passes 2 of 7 health tests.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Bio Key International Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 13, 2026
Friday Β· in 18 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 13, 2026 | Q2 '26 | Time not announced | 8-K β |
| Apr 16, 2026 | Q1 '26 | Time not announced | 8-K β |
| Mar 3, 2026 | Q4 '25 | Time not announced | 8-K β |
| Nov 14, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 13, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 9, 2025 | Q1 '25 | Time not announced | 8-K β |
| Mar 27, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 14, 2024 | Q3 '24 | Time not announced | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Bio Key International Inc had $5.9M of revenue in fiscal 2025, down 14.3% on the year before. Over five years, revenue changed +15.9% a year on average. Its operating margin was β115.0%, down 57.1Β pts: of every 100 in sales, about β115 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Bio Key International Inc lost $7.2M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$4.7M in fiscal 2025, β78.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Bio Key International Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.8M | $2.6M | $0.5M | $0.4M | $2.7M |
| Debt incl. finance leases | $0.0M | $3.0M | $0.3M | $0.0M | β |
| Debt / equity | 0.0x | 0.6x | 0.3x | 0.0x | β |
| Interest coverage | β274.6x | β945.1x | β40.4x | β22.8x | β112.3x |
| Current ratio | 7.0x | 1.6x | 0.8x | 0.4x | 1.5x |
| Quick ratio | 4.5x | 0.8x | 0.7x | 0.3x | 1.3x |
| Total assets | $17.8M | $11.3M | $4.5M | $8.6M | $8.3M |
| Total liabilities | $2.2M | $6.0M | $3.5M | $4.8M | $3.2M |
| Shareholders' equity | $15.6M | $5.3M | $1.1M | $3.8M | $5.1M |
| Net debt (β = net cash) | β$7.8M | $0.4M | β$0.2M | β$0.4M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Bio Key International Inc passes 2 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 8 | 2 / 8 | 3 / 8 | 4 / 8 | 3 / 9 | 2 / 8 | 3 / 8 | 4 / 8 | 2 / 7 |
| Accruals ratio | 1.5% | β10.8% | β37.8% | β179.6% | β37.8% | 19.4% | β39.0% | β59.6% | β21.1% | β29.4% |
| Altman Z'' | β3.47 | β7.26 | β10.30 | β128.48 | β1.22 | β9.01 | β36.39 | β103.89 | β53.27 | β56.29 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $3.0M | $6.3M | $4.0M | $2.3M | $2.8M | $5.1M | $7.0M | $7.8M | $6.9M | $5.9M |
| Net interest income | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Gross profit | $2.2M | $3.1M | β$0.1M | β$0.2M | $2.0M | $3.4M | $4.6M | $1.4M | $5.6M | $4.6M |
| Research and development | $2.0M | $1.7M | $1.4M | $1.3M | $1.4M | $2.4M | $3.3M | $2.4M | $2.5M | $2.6M |
| Operating income | β$4.2M | β$4.3M | $0.0M | β$1.1M | β$5.2M | β$4.9M | β$9.9M | β$8.8M | β$4.0M | β$6.8M |
| Interest expense | β | β | β | $1.1M | $4.3M | $0.0M | $0.0M | $0.2M | $0.2M | $0.1M |
| Pretax income | β | β | β | β | β | $0.0M | β$11.9M | β$8.7M | β$4.3M | β$7.1M |
| Income tax | β$0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β$0.0M | β$0.1M | β$0.0M | $0.0M |
| Net income | β$4.2M | β$4.3M | β$6.9M | β$14.6M | β$9.7M | β$5.1M | β$11.9M | β$8.5M | β$4.3M | β$7.2M |
| Net income to common | β$5.0M | β$5.0M | β$8.5M | β$14.6M | β$9.8M | β$5.1M | β | β | β | β |
| Diluted EPS | β$0.89 | β$0.76 | β$0.73 | β$8.21 | β$2.08 | β$0.65 | β | β | β | β |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.01B | β | β | β | β |
| Cash flow | ||||||||||
| Cash from operations | β$4.4M | β$2.5M | β$1.6M | β$1.9M | β$5.0M | β$9.0M | β$6.2M | β$3.8M | β$2.9M | β$4.7M |
| Capital expenditure | $0.1M | $0.2M | $0.1M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Free cash flow | β$4.5M | β$2.6M | β$1.7M | β$1.9M | β$5.0M | β$9.0M | β$6.3M | β$3.8M | β$2.9M | β$4.7M |
| Depreciation and amortization | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | $0.3M | $0.9M | $0.9M | $0.9M | $0.8M | $0.3M | $0.4M | $0.3M | $0.2M | $0.2M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.1M | $0.3M | $0.3M | $0.1M | $17.0M | $7.8M | $2.6M | $0.5M | $0.4M | $2.7M |
| Total debt | β | β | β | β | $0.2M | $0.0M | $3.0M | $0.3M | $0.0M | β |
| Current assets | $4.9M | $7.0M | $4.2M | $1.4M | $18.9M | $14.0M | $9.0M | $2.6M | $1.9M | $4.5M |
| Current liabilities | $1.8M | $2.3M | $1.2M | $4.4M | $1.9M | $2.0M | $5.5M | $3.2M | $4.6M | $3.1M |
| Inventory | $0.5M | $0.9M | $1.0M | $0.4M | $0.3M | $4.9M | $4.4M | $0.4M | $0.4M | $0.4M |
| Property and equipment, net | $0.1M | $0.2M | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.2M | $0.1M | $0.1M |
| Goodwill | β | β | β | β | $1.3M | $1.3M | $0.0M | β | β | β |
| Intangible assets | $0.1M | $0.2M | $0.2M | $0.2M | $1.5M | $1.3M | $1.8M | $1.4M | $1.1M | $0.8M |
| Total assets | $17.3M | $16.1M | $11.7M | $2.5M | $22.5M | $17.8M | $11.3M | $4.5M | $8.6M | $8.3M |
| Total liabilities | $1.8M | $2.3M | $1.2M | $4.8M | $2.2M | $2.2M | $6.0M | $3.5M | $4.8M | $3.2M |
| Shareholders' equity | $15.5M | $13.8M | $10.5M | β$2.3M | $20.3M | $15.6M | $5.3M | $1.1M | $3.8M | $5.1M |
| Margins | ||||||||||
| Gross margin | 75.5% | 48.6% | β3.0% | β8.5% | 72.0% | 67.3% | 65.2% | 18.5% | 81.4% | 76.9% |
| Operating margin | β141.2% | β67.8% | 0.0% | β47.1% | β183.4% | β96.6% | β141.4% | β113.8% | β57.9% | β115.0% |
| EBITDA margin | β139.6% | β67.0% | 2.1% | β43.5% | β180.4% | β95.6% | β140.7% | β112.8% | β56.5% | β113.6% |
| Net margin | β140.8% | β67.8% | β169.8% | β643.4% | β341.0% | β99.0% | β169.6% | β109.9% | β62.1% | β120.6% |
| FCF margin | β151.2% | β41.8% | β41.2% | β82.9% | β175.8% | β176.4% | β89.9% | β48.9% | β42.2% | β78.8% |
| Net interest share of revenue | 0.0% | 0.0% | 0.0% | β | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β115.0% | β49.7% | β137.3% | β792.6% | β93.8% | β |
| Return on capital employed | β27.2% | β31.1% | 0.0% | 56.4% | β25.2% | β31.3% | β168.5% | β677.1% | β98.7% | β131.1% |
| Return on equity | β27.1% | β29.3% | β56.7% | β356.6% | β107.2% | β28.2% | β113.9% | β267.8% | β177.9% | β161.2% |
| Return on assets | β24.2% | β25.6% | β49.5% | β205.6% | β77.3% | β25.1% | β81.8% | β107.5% | β65.5% | β84.6% |
| Return on tangible equity | β32.6% | β37.2% | β82.7% | β | β55.7% | β38.8% | β336.6% | β | β160.8% | β167.4% |
| Growth | ||||||||||
| Revenue growth | β | 111.8% | β35.8% | β43.9% | 25.1% | 80.3% | 37.3% | 10.5% | β10.6% | β14.3% |
| Share count change | β | 18.8% | 74.9% | β84.7% | 164.4% | 65.8% | β | β | β | β |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.0x | 0.0x | 0.6x | 0.3x | 0.0x | β |
| Interest coverage | β | β | β | β1.0x | β1.2x | β274.6x | β945.1x | β40.4x | β22.8x | β112.3x |
| Current ratio | 2.7x | 3.0x | 3.4x | 0.3x | 10.1x | 7.0x | 1.6x | 0.8x | 0.4x | 1.5x |
| Quick ratio | 2.4x | 2.6x | 2.6x | 0.2x | 9.9x | 4.5x | 0.8x | 0.7x | 0.3x | 1.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.8% | 2.6% | 1.3% | 1.3% | 1.3% | 0.8% | 1.2% | 0.0% | 0.2% | 0.2% |
| Stock comp / revenue | 8.8% | 14.9% | 23.3% | 41.8% | 27.9% | 6.2% | 5.5% | 3.4% | 3.5% | 2.8% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 2.0 | 3.0 | 4.0 | 3.0 | 2.0 | 3.0 | 4.0 | 2.0 |
| Altman Z'' | β3.5 | β7.3 | β10.3 | β128.5 | β1.2 | β9.0 | β36.4 | β103.9 | β53.3 | β56.3 |
| Accruals ratio | 1.5% | β10.8% | β37.8% | β179.6% | β37.8% | 19.4% | β39.0% | β59.6% | β21.1% | β29.4% |
Source: SEC EDGAR XBRL filings (CIK 0001019034). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
